fruquintinib plus capecitabine

DRUG4 trials

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University, Beijing Friendship Hospital, Chinese Academy of Medical Sciences, Fudan University

Conditions

Colorectal CancerColorectal Cancer Stage IVMetastatic Colorectal CancerUnresectable Metastatic Colorectal Cancer

Phase 1

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Chinese Academy of Medical SciencesMetastatic Colorectal Cancer

Start: 2022-04-12End: 2024-08-31Target: 48Updated: 2022-08-18

Phase 2

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityColorectal Cancer

Start: 2021-03-01End: 2023-02-01Target: 112Updated: 2022-07-26

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Beijing Friendship HospitalUnresectable Metastatic Colorectal Cancer

Start: 2021-12-08End: 2024-06-30Target: 49Updated: 2022-08-18

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

Fudan UniversityColorectal Cancer, Colorectal Cancer Stage IV

Start: 2022-07-31End: 2025-07-31Target: 116Updated: 2022-07-12

Related Papers

A randomized phase II trial of fruquintinib plus capecitabine versus capecitabine alone as maintenance therapy following first-line chemotherapy in metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2026-05-27

Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study.

2025-02-13

Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.

Journal of Clinical Oncology2024-06-01

Initial efficacy evaluation of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer (mCRC): A randomized, controlled, phase Ib/II study.

Journal of Clinical Oncology2024-01-20